In this light, identifying the SMYD3 regions that interact with P-proteins and using purified P-tripeptides to interfere with these physical interactions (Fig. 5B–E) may offer a potential avenue to develop anticancer therapeutics and/or to resensitize resistant cancers to chemotherapeutic DNA-damaging agents. Here, SMYD3 is linked to cancer.